DRAPER, Utah, Aug. 08, 2023 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its second quarter of fiscal 2024 financial results following the close of regular stock market trading hours on Tuesday, September 5, 2023. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, September 5, 2023, at 4:30 p.m. ET during which management will review the Company’s second quarter results.
HealthEquity Second Quarter Fiscal Year 2024 Results Conference Call | |
Date: | September 5, 2023 |
Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
Dial-In: | 1-833-630-1956 (US and Canada) 1-412-317-1837 (International) |
Conference ID: | HealthEquity, Inc. call |
Webcast: | www.ir.healthequity.com |
A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.
The Company also announced that its management team plans to present and meet with investors at the following upcoming investor conferences:
2023 Wells Fargo Healthcare Conference | |
Location: | Encore Hotel, Boston |
Date: | September 6, 2023 |
Time: | 3:45 p.m. Eastern Time |
Webcast: | none |
2023 RW Baird Global Consumer, Healthcare Conference | |
Location: | InterContinental New York Barclay |
Date: | September 12, 2023 |
Time: | 2:00 p.m. Eastern Time |
Webcast: | none |
2023 Barrington Virtual Fall Investor Conference | |
Location: | Virtual |
Date: | September 14, 2023 |
Time: | 1x1 meetings only |
Webcast: | none |
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our 15 million benefit accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our most recent Annual Report on Form 10-K and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$98.98 |
Daily Change: | 3.28 3.43 |
Daily Volume: | 1,262,237 |
Market Cap: | US$8.640B |
November 12, 2024 October 15, 2024 September 03, 2024 September 03, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB